Analyst firms · Daiwa · BMY
Daiwa BMY price target and rating history
Bristol-Myers Squibb Company (BMY) · Health Care
Daiwa rates Bristol-Myers Squibb Company (BMY) Neutral with a $42 price target, as of its latest action on Aug 5, 2025. It has published 4 rating actions on BMY since June 2023, including 1 upgrade and 2 downgrades. Across 8 firms with a BMY price target in the last 12 months, the median target is $61.50.
- Current rating
- Neutral
- Price target
- $42
- Median target, all firms
- $61.50
- Actions on BMY
- 4
Daiwa price target on BMY
Every Daiwa rating on BMY
- Aug 5, 2025
- Nov 13, 2024
- Nov 2, 2023
- Jun 28, 2023
How other firms rate BMY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Market Perform | $59 | Oct 5, 2026 |
| Argus Research | Buy | $75 | Aug 5, 2026 |
| RBC Capital Markets | Sector Perform | $60 | Feb 25, 2026 |
| Barclays | Overweight | $75 | Feb 20, 2026 |
| UBS | Buy | $65 | Jan 7, 2026 |
| BofA Securities | Buy | $61 | Dec 15, 2025 |
| Guggenheim | Buy | $62 | Dec 12, 2025 |
| Scotiabank | Sector Perform | $45 | Nov 13, 2025 |
Questions about Daiwa and BMY
- What is Daiwa's price target for BMY?
- Daiwa's latest stated price target for Bristol-Myers Squibb Company (BMY) is $42, from its action on Aug 5, 2025.
- What is Daiwa's rating on BMY?
- Daiwa rates BMY Neutral, a neutral rating, as of Aug 5, 2025.
- When did Daiwa last change its view on BMY?
- On Aug 5, 2025, Daiwa downgrades to Neutral from Outperform, price target $42.
- How does Daiwa's BMY target compare with other analysts?
- Across 8 firms with a BMY price target in the last 12 months, the median target is $61.50.
More BMY rating histories
All Daiwa ratingsBMY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.